Every RPM platform marketed today claims some form of intelligent alert logic — anomaly detection, predictive deterioration scoring, trend-based alerting. The marketing terms are largely interchangeable. The underlying rigor is not.
If you're evaluating RPM platforms for clinical deployment, or if you've already deployed one and you're relying on its alert logic to make clinical decisions, you need to understand what validation actually means in this context — and what questions to ask. Most vendor validation claims don't hold up under close examination.
What Validation Means
Clinical validation of an anomaly detection algorithm requires, at minimum, three things. First, a clearly defined clinical endpoint: what is the algorithm trying to detect? "Deterioration" isn't specific enough. Is it detecting hypertensive urgency? Impending COPD exacerbation? Acute decompensated heart failure? Each requires different input features, different sensitivity/specificity tradeoffs, and different time horizons.
Second, an independent validation dataset — patient data that was not used during model training, ideally from a different patient population and clinical setting than the training data. An algorithm that performs well on training data but hasn't been tested on external data hasn't been validated; it's been overfitted. This distinction matters more than most vendors want to acknowledge.
Third, performance metrics that are clinically meaningful. An algorithm that detects 95% of deterioration events sounds impressive until you learn it also alerts on 40% of non-events. In an RPM context, that false positive rate would make the alert system functionally useless within weeks. Sensitivity and specificity need to be reported together, along with the positive predictive value at the expected prevalence of the condition in your patient population.
FDA Clearance and What It Does and Doesn't Tell You
Some RPM alert algorithms are marketed with FDA 510(k) clearance for their underlying device or alert logic. This matters, but it doesn't mean what many buyers assume it means. 510(k) clearance for a medical device software function typically means the FDA has determined that the software is substantially equivalent to a predicate device that was already on the market — not that the agency has independently validated the algorithm's clinical performance on your patient population.
Cleared software can still perform poorly in specific clinical contexts, in specific patient demographics, or when used in combination with certain device configurations that differ from the clearance test conditions. Clearance is a regulatory starting point, not a clinical performance guarantee.
The FDA's 2023 guidance on AI/ML-based Software as a Medical Device (SaMD) provides a more detailed framework for how continuously updated algorithms should be monitored post-deployment. If a platform you're evaluating is updating its alert algorithms based on real-world data — which is how most modern anomaly detection systems work — ask how those updates are governed and what change notification process is in place. Changes to algorithm logic can affect clinical performance without triggering a visible product change.
Specific Claims to Question
When a vendor says their system "predicts deterioration 48 hours in advance" with high accuracy, the useful follow-up questions are: accuracy measured how, on which patient population, using what clinical outcome as the ground truth, and what was the false positive rate? If those numbers aren't immediately available in a clinical validation paper or technical white paper, they haven't been rigorously measured.
Vendor claims about model performance that are based on internal retrospective data only — where the vendor analyzed their own patient data using their own outcome definitions — should be treated with significant skepticism. Retrospective analyses can be useful for algorithm development, but prospective validation on independent datasets is the minimum standard for clinical deployment claims.
What Thoughtful Validation Looks Like in Practice
The algorithms with the strongest published clinical evidence in RPM contexts are not the most sophisticated. They're the most carefully characterized. Threshold-based systems with patient-specific baseline calibration and tiered alert logic have more clinical evidence behind them than most of the trend prediction models currently marketed as "AI-powered."
That's not an argument against trend-based or predictive approaches — they have real potential. It's an argument for being honest about where the evidence is strong and where it isn't yet. A care team making clinical decisions based on algorithm output is owed that transparency.
When evaluating any RPM platform's detection logic, ask for the validation study, ask about the patient population it was validated on, and ask specifically about false positive rates. If the vendor can't answer those questions, the algorithm hasn't been validated in any meaningful clinical sense.
The goal of anomaly detection in RPM is to support clinical judgment — to surface relevant signals in a large data stream so that human clinicians can act on them. That's a more modest and more achievable claim than "predict deterioration." It's also the claim that the published evidence actually supports.